Paul G Richardson
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403-e414.
09.05.2022Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
09.05.2022Lancet Haematol 2022; 9:e403-e414
Dimopoulos Meletios A, Richardson Paul G, Bahlis Nizar, Grosicki Sebastian, Cavo Michele, Beksac Meral, Legieć Wojciech, Liberati Anna Marina, Goldschmidt Hartmut, Belch Andrew, Magen Hila, Larocca Alessandra, Laubach Jacob, Petrucci Maria Teresa, Reece Donna, White Darrell, Mateos Maria-Victoria, Špička Ivan, Lazaroiu Mihaela, Berdeja Jesus G, Kaufman Jonathan L, Jou Ying-Ming, Ganetsky Alex, Popa McKiver Mihaela, Lonial Sagar, Weisel Katja, Driessen Christoph
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Richardson P, Goldschmidt H, Harousseau J, Dytfeld D, Mellqvist U, Chng W, Hou J, Bergsagel P, Riva E, Leleu X, Bladé J, Driessen C, Quach H, Ocio E, Vesole D, Waage A, Laubach J, Munshi N, Gay F, Dimopoulos M, Rajkumar S, Mateos M, Cook G, Nahi H, Harrison S, Sezer O, Holstein S, Zweegman S, Usmani S, Boccadoro M, Hari P, Kaiser M, Costa L, Beksac M, Maiolino A, Leal da Costa F, Sidana S, Jurczyszyn A, Facon T, Durie B, Yong K, Martin T, Schjesvold F, Terpos E, Mikhael J, Ludwig H, Bahlis N, Zamagni E, Davies F, San Miguel J, Kumar S, Raje N, van de Donk N, Lonial S, Berdeja J, Hungria V, Baz R, Weisel K, Vangsted A, Fonseca R, Engelhardt M, Sonneveld P, Einsele H, João C, Anderson K, Hájek R, Lentzsch S, Kristinsson S, Cavo M, Moreau P. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021; 22:e105-e118.
01.01.2021Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
01.01.2021Lancet Oncol 2021; 22:e105-e118
Richardson Paul G, Goldschmidt Hartmut, Harousseau Jean-Luc, Dytfeld Dominik, Mellqvist Ulf-Henrik, Chng Wee Joo, Hou Jian, Bergsagel Peter Leif, Riva Eloisa, Leleu Xavier, Bladé Joan, Driessen Christoph, Quach Hang, Ocio Enrique M, Vesole David H, Waage Anders, Laubach Jacob, Munshi Nikhil C, Gay Francesca, Dimopoulos Meletios A, Rajkumar S Vincent, Mateos Maria-Victoria, Cook Gordon, Nahi Hareth, Harrison Simon, Sezer Orhan, Holstein Sarah, Zweegman Sonja, Usmani Saad Z, Boccadoro Mario, Hari Parameswaran, Kaiser Martin, Costa Luciano J, Beksac Meral, Maiolino Angelo, Leal da Costa Fernando, Sidana Surbhi, Jurczyszyn Artur, Facon Thierry, Durie Brian G M, Yong Kwee, Martin Thomas, Schjesvold Fredrik, Terpos Evangelos, Mikhael Joseph, Ludwig Heinz, Bahlis Nizar, Zamagni Elena, Davies Faith, San Miguel Jesús, Kumar Shaji K, Raje Noopur, van de Donk Niels, Lonial Sagar, Berdeja Jesus G, Hungria Vania, Baz Rachid, Weisel Katja, Vangsted Annette, Fonseca Rafael, Engelhardt Monika, Sonneveld Pieter, Einsele Hermann, João Cristina, Anderson Kenneth C, Hájek Roman, Lentzsch Suzanne, Kristinsson Sigurdur Y, Cavo Michele, Moreau Philippe
An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
Downey-Kopyscinski S, Overkleeft H, Driessen C, Richardson P, Mitsiades C, Florea B, Bhatt A, Gautier M, Daily E, Kisselev A. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2018; 2:2443-2451.
09.10.2018An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
09.10.2018Blood Adv 2018; 2:2443-2451
Downey-Kopyscinski Sondra, Overkleeft Herman S, Driessen Christoph, Richardson Paul G, Mitsiades Constantine S, Florea Bogdan I, Bhatt Ananta, Gautier Marc, Daily Ellen W, Kisselev Alexei F